Who is a candidate for this treatment

Many people with hip osteoarthritis reach a point where physiotherapy has plateaued, painkillers are no longer holding, and previous injections — corticosteroid or hyaluronic acid — have stopped providing lasting relief. They are not yet at the stage where their surgeon is pressing for a hip replacement, but they need something more than conservative management can now offer. ChondroFiller injection is designed for precisely this in-between position.

The patients who tend to be best suited are those with mild-to-moderate diffuse hip osteoarthritis — typically Kellgren-Lawrence Grade III or IV — where the hip joint still has measurable space visible on X-ray. That preserved joint space is an important signal: it indicates there is still a surface worth protecting. Most patients in this group are in their 50s or 70s, though younger adults who are delaying surgery for work or lifestyle reasons are also a relevant group.

Some clear inclusion signals:

• Hip pain and stiffness that has not responded adequately to physiotherapy, activity modification, and analgesia
• Previous intra-articular injections (corticosteroid or hyaluronic acid) that provided short-term relief but are no longer effective
• X-ray confirming residual joint space, without end-stage bone-on-bone narrowing
• A preference to defer total hip replacement while maintaining day-to-day function

Conversely, the treatment is not appropriate where joint space has effectively been lost, where there is advanced bone-on-bone contact across the hip, or where the clinical picture already points to urgent hip replacement. Individual suitability always requires a consultant assessment — these signals are a starting guide, not a substitute for clinical judgement.

What ChondroFiller is and how it works in the hip joint

ChondroFiller is a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany and imported into the UK under a named-patient prescription. At its core it is an acellular injectable scaffold made from purified Type I collagen — it contains no donor cells and no hyaluronic acid.

The procedure itself is an outpatient appointment rather than a surgical admission. Under ultrasound guidance, the collagen material is injected directly into the hip joint, where it gels in situ within roughly three to five minutes, settling over the worn articular surfaces. No incisions, no general anaesthetic, and no bone drilling are involved.

Once in place, the scaffold works through a process called acellular matrix-induced chondrogenesis — in plain terms, a structure that the patient's own cells migrate into and gradually remodel. Mesenchymal progenitor cells recruited from the synovium and subchondral bone travel into the collagen matrix, differentiate, and progressively convert it into fibrocartilage-like repair tissue over a period of three to six months as the original scaffold resorbs. This means ChondroFiller supports the body's own repair processes rather than simply lubricating the joint or filling it with a permanent synthetic material.

This distinction matters when comparing it with other intra-articular options. Hyaluronic acid is a palliative lubricant that does not promote biological repair. Permanent polyacrylamide hydrogels (such as Arthrosamid/PAAG) are non-degradable fillers that remain in the joint indefinitely. ChondroFiller occupies a different category: a temporary biodegradable scaffold that triggers endogenous biological remodelling.

In the bridge-to-hip-replacement role specifically, the injected gel acts as an additive cushioning layer applied over worn hip surfaces — reducing friction and mechanical stress from the top down, rather than attempting to rebuild a focal defect from its base. The goal is symptom relief and functional stabilisation, buying meaningful time before total hip replacement becomes necessary.

What the clinical evidence shows

Published outcome data for ChondroFiller comes predominantly from European knee studies — and that limitation is worth stating plainly at the outset. Perez-Carro et al. (2021, PMC8322278) confirmed the procedure is viable for full-thickness acetabular cartilage defects in the hip with promising early findings, but the authors themselves noted that long-term, large-scale randomised data for the hip indication are not yet available. Patients considering this treatment for the hip should understand that the broader outcomes literature is being extrapolated from knee experience.

With that context in place, the figures from knee studies provide a useful reference point. In those studies, MOCART imaging scores — which assess the structural quality of repair tissue on MRI — range consistently from 81.6 to 84.3, indicating that more than 80% of the treated defect fills with tissue that integrates well with surrounding native cartilage. Scores mature progressively, rising from a mean of 65.3 at four weeks to 81.6 at one year, suggesting ongoing biological remodelling across that window.

On patient-reported function, the Jerosch et al. prospective study recorded a mean IKDC improvement of 32.4 points sustained at three-year follow-up — well above the accepted minimal clinically important difference of 16.7 points for that scale. Across available studies, symptom-relief success rates of 70–85% are reported.

The safety profile is a notable strength. The complication rate is approximately 0%, and the reoperation rate sits at 3–8% — considerably lower than microfracture (up to 41% reoperation) or ACI/MACI (complications up to 17%; reoperation up to 37%).

No published evidence currently quantifies how many months or years hip replacement is deferred following a ChondroFiller injection specifically. That data gap reflects the relative novelty of the hip injection indication rather than a known negative finding.

How ChondroFiller compares with other hip injections

Four intra-articular options come up most often in hip osteoarthritis discussions, and each occupies a genuinely different role in the care pathway.

Corticosteroid reduces joint inflammation quickly, making it useful for acute flare control or as a short-term holding measure before further assessment. Its limitation is durability: relief typically spans weeks to a few months, and — importantly — repeated triamcinolone injections were associated with measurable cartilage volume loss over two years in a JAMA 2017 randomised trial (McAlindon et al.). For that reason, corticosteroid is generally regarded as a symptom-management tool rather than a cartilage-preservation strategy.

Hyaluronic acid (viscosupplementation) adds lubrication to the synovial environment rather than repairing tissue. It may ease symptoms in the short term for some patients, though guideline support for its use specifically in the hip remains inconsistent — bodies including AAOS and ACR offer limited endorsement, while OARSI's position is conditional.

Arthrosamid / polyacrylamide hydrogel (PAAG) is a permanent, non-biodegradable synthetic material that remains in the joint indefinitely after injection. It is not a regenerative scaffold and does not promote biological repair; its role is mechanical cushioning as a durable filler, and it should not be grouped with ChondroFiller as though the two share a mechanism.

ChondroFiller differs from all three. As a biodegradable collagen scaffold it is the only option in this group that actively recruits the patient's own progenitor cells to remodel the treatment zone. It does not replicate the anti-inflammatory effect of corticosteroid or the lubricating role of hyaluronic acid — it adds a structural-repair dimension that neither of those options provides.

The treatment pathway and what recovery looks like

Booking an assessment is the starting point. The treatment itself is an ultrasound-guided injection delivered at a private MSK clinic — compact and outpatient-based — and recovery follows a predictable arc from there.

For the first few days after the injection, crutch-assisted walking is advised while the scaffold stabilises within the joint. Clinical benefit does not arrive immediately; ChondroFiller is not an analgesic, and improvement develops progressively as recruited progenitor cells remodel the collagen matrix. Full functional recovery is expected at three to six months as the repair tissue matures. Patients who anticipate the same rapid relief as a corticosteroid injection are likely to find the early weeks understated — the functional gains build over that window rather than arriving at once.

Cost and access

ChondroFiller is not NHS-funded and is not covered by Bupa, AXA, or comparable UK private medical insurers. It is imported from Germany on a self-funded, named-patient prescription basis, arranged by the treating clinic for each individual patient. Private pricing starts at approximately £3,000 for a single-box course, rising to £5,500 (two boxes) or £8,000 (three boxes); each package covers the consultation, ultrasound guidance, the product, the injection appointment, and a six-week clinical follow-up.

Lincolnshire Hip is part of the MSK Doctors group, with clinics accessible from Sleaford and Grantham, and accepts patients without GP referral for hip assessment.

Realistic expectations and when hip replacement is still the right step

ChondroFiller does not cure hip osteoarthritis and cannot reverse the joint damage already present. For selected patients it may offer a meaningful interval of improved function and reduced pain before surgery becomes the next step — but the precise length of that interval in hip osteoarthritis remains unquantified. No published study to date has measured the deferral of total hip replacement in a hip OA cohort treated specifically with the injectable form of ChondroFiller, and any claim of a defined delay would exceed what the evidence currently supports.

When joint space has narrowed significantly, or daily function is severely compromised despite a full conservative pathway, total hip replacement remains the most reliable long-term solution. With approximately 58% of implants estimated to last 25 years, arthroplasty is an effective and well-established procedure — not a failure state, but the appropriate next step when joint preservation options are no longer adequate.

ChondroFiller fits best as one component of the broader hip preservation pathway, considered before surgery is clearly indicated rather than instead of it when arthroplasty is already the right clinical decision. Deferring surgery past the point where outcomes may be compromised serves no patient well. When to proceed — and whether the current state of the hip joint makes an injection a worthwhile interim step — is a question a consultant-led assessment should answer individually.